Codelivery of 1α,25-Dihydroxyvitamin D3 and CYP24A1 Inhibitor VID400 by Nanofiber Dressings Promotes Endogenous Antimicrobial Peptide LL-37 Induction.
Quick Facts
What This Study Found
The nanofiber dressings significantly increased hCAP18/LL-37 expression in wounds compared to free drugs.
Key Numbers
How They Did This
The study involved creating nanofiber dressings that coencapsulated 1α,25-dihydroxyvitamin D3 and VID400, followed by testing their effects on gene expression in vitro and in vivo.
Why This Research Matters
Surgical site infections are a major concern in healthcare, and enhancing the body's natural defenses could lead to better patient outcomes. This innovative dressing could provide a new strategy for infection prevention.
What This Study Doesn't Tell Us
The study primarily involved animal models, and further research is needed to confirm effectiveness in humans.
Trust & Context
- Original Title:
- Codelivery of 1α,25-Dihydroxyvitamin D3 and CYP24A1 Inhibitor VID400 by Nanofiber Dressings Promotes Endogenous Antimicrobial Peptide LL-37 Induction.
- Published In:
- Molecular pharmaceutics, 19(3), 974-984 (2022)
- Authors:
- Su, Yajuan(2), Ganguli-Indra, Gitali(2), Bhattacharya, Nilika, Logan, Isabelle E, Indra, Arup K, Gombart, Adrian F, Wong, Shannon L, Xie, Jingwei
- Database ID:
- RPEP-06519
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06519APA
Su, Yajuan; Ganguli-Indra, Gitali; Bhattacharya, Nilika; Logan, Isabelle E; Indra, Arup K; Gombart, Adrian F; Wong, Shannon L; Xie, Jingwei. (2022). Codelivery of 1α,25-Dihydroxyvitamin D3 and CYP24A1 Inhibitor VID400 by Nanofiber Dressings Promotes Endogenous Antimicrobial Peptide LL-37 Induction.. Molecular pharmaceutics, 19(3), 974-984. https://doi.org/10.1021/acs.molpharmaceut.1c00944
MLA
Su, Yajuan, et al. "Codelivery of 1α,25-Dihydroxyvitamin D3 and CYP24A1 Inhibitor VID400 by Nanofiber Dressings Promotes Endogenous Antimicrobial Peptide LL-37 Induction.." Molecular pharmaceutics, 2022. https://doi.org/10.1021/acs.molpharmaceut.1c00944
RethinkPeptides
RethinkPeptides Research Database. "Codelivery of 1α,25-Dihydroxyvitamin D3 and CYP24A1 Inhibito..." RPEP-06519. Retrieved from https://rethinkpeptides.com/research/su-2022-codelivery-of-125dihydroxyvitamin-d3
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.